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Background: The chemokines keratinocyte-Derived Cytokine (KC) and macrophage inflammatory protein (MIP)-2,
murine equivalents of human interleukin 8, have been implicated in remote injury after acute hind limb ischemia/
reperfusion (I/R). These studies were designed to determine whether the cytokines responsible for remote tissue injury
are also synthesized and accumulate in the ischemic or reperfused hind limb.
Methods:B6, 129SF2/Jmicewere subjected to either 3 hours of unilateral hind limb ischemia alone (IA) or 3 hours of ischemia
followed by 4 or 24 hours of reperfusion (I/R). After IA or I/R, experimental and control (nonischemic) contralateral hind
limbs were harvested for analysis of protein content, messenger RNA (mRNA), tissue edema, and viability.
Results: IA did not increase KC or MIP-2 mRNA or protein levels. In contrast, I/R resulted in a 15- and 10-fold increase
in KC mRNA after 4 and 24 hours of reperfusion, respectively. KC protein levels were increased 10-fold after 4 hours of
reperfusion and 30-fold after 24 hours (vs IA or sham; P < .001). MIP-2 mRNA transiently increased 42-fold after 4
hours of reperfusion but decreased to basal levels after 24 hours of reperfusion. Despite the relative increase in MIP-2
mRNA by 4 hours of reperfusion, significantly increased (8- to 10 fold) MIP-2 protein levels were not detected until 24
hours of reperfusion only in the reperfused limbs. Tissue edema was increased significantly (P< .01) compared with sham
after just 4 hours of reperfusion and remained increased at 24 hours. Tissue viability decreased 52% after 4 hours of
reperfusion and did not change significantly by 24 hours.
Conclusions: Skeletal muscle is a site of significant ongoing chemokine synthesis during reperfusion. The persistent
increase in muscle chemokine levels at 24 hours of reperfusion was not associated with increased edema or injury. The role
of these chemokines during reperfusion may be further investigated by local or oral administration of chemokines or
chemokine receptor antagonists. ( J Vasc Surg 2005;42:337-43.)
Clinical Relevance: I/R injury remains an important clinical problem across a variety of surgical specialties. In the critical
care arena, serum levels of proinflammatory cytokines have been useful in predicting the mortality associated with acute
respiratory distress syndrome and sepsis. In this article, the data presented indicate that murine skeletal muscle produces
potent proinflammatory neutrophil and macrophage chemokines during reperfusion, but not during ischemia. These
findings suggest that measurement of tissue and/or serum levels of chemokines during reperfusion may be an important
adjunct to predicting tissue injury along with ongoing inflammation during the clinical course of reperfusion injury.
Within the vascular system, severe inflammatory responses are usually associated with thrombotic events. New techniques
to noninvasively image thrombin activation (by usingmagnetic resonance imaging) in reperfused limbsmay coincide with
the pattern of murine skeletal muscle chemokine expression in humans. The data suggest that reperfusion is when
chemokine mRNA and protein synthesis increase. Within the time periods studied in these experiments, the chemokine
component of the inflammatory response remained in the reperfused, rather than the systemic nonreperfused, tissue. This
observation may underestimate the degree of the systemic response to ischemia because the single mouse hind limb
represents only 7% of the mouse total body area, whereas the human limb represents nearly 18% of the adult body area.
Despite this shortcoming, these data provide potential temporal and quantitative information regarding the location and
magnitude of chemokine synthesis in skeletal muscle during reperfusion.From the Division of Vascular and Endovascular Surgerya and Department
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doi:10.1016/j.jvs.2005.04.046Chemokines are multifunctional mediators mainly respon-
sible for leukocyte recruitment to inflamed tissues. Mem-
bers of the chemokine superfamily of cytokines share ho-
mologous sequences and a highly conserved cysteine motif.
The chemokines can be divided into four broad categories,
depending on whether the first two cysteines are separated
(CXC) or not (CC) by an intervening amino acid. If the
second cysteine is missing, then these chemokines are clas-
sified as C; if the first pair of cysteines are separated by three
intervening amino acids, then the classification CX3C is
applied. Cytokines of the CXC family also have a pivotal
role in the control of both inflammation and angiogenesis
as a result of the shared expression of their specific receptors
by leukocytes and endothelial cells.1 Experimental analysis
of the pathophysiology of postischemic skeletal muscle
tissue injury in a variety of animal models implicates leuko-
337
JOURNAL OF VASCULAR SURGERY
August 2005338 Hua et alcytes as primarymediators of tissue injury and the no-reflow
phenomenon, leading to a paradoxical increase in injury.2,3
To date, much of the experimental data evaluating the
cytokine response to skeletal muscle ischemia/reperfusion
(I/R) have been focused on interleukin (IL)-1 and tumor
necrosis factor .4 In addition to these well-known cyto-
kines, there is redundancy in the development of the im-
mune response, particularly among different cytokines and
chemokines. Thus, it is not surprising that the role of the
CXC chemokines in models of organ I/R is now under
intense scrutiny. In fact, experiments with hepatic and
myocardial tissue have shown that the potent neutrophil
chemoattractants keratinocyte-derived cytokine (KC) and
macrophage inflammatory protein (MIP)-2 play a crucial
role in both local and remote tissue injury.5-7 Detailed
studies have localized these chemokines to serum8 and
systemic tissues (lung and kidney) after hind limb I/R.9,10
Recent work in our laboratory has indicated that hu-
man microvascular endothelial cells produce large amounts
of IL-8 under in vitro conditions of I/R.11 IL-8 was the
first human CXC chemokine available in large enough
quantities to allow for receptor characterization. In mice,
MIP-2 and KC share the proinflammatory and angiogenic
effects of IL-8 through a receptor that shares 70% homol-
ogy with the human IL-8 receptor.12-15 This study sought
to determine whether KC and MIP-2 are synthesized lo-
cally in skeletal muscle during I/R and to determine
whether their appearance in the tissue correlates with
changes in the steady-state levels of their respective messen-
ger RNA (mRNA) or with differences in the extent of
postischemic tissue injury/edema.
METHODS
Controlled-tension tourniquet. The controlled-ten-
sion tourniquet was used in conjunction with laser Doppler
imaging (Moor Instruments Inc, Wilmington, Del) to in-
duce and document reproducible levels of hind limb I/R in
the proximal hind limb of the mouse as previously de-
scribed.16 Reperfusion was initiated by releasing tension on
the tourniquet. Core temperature in the mouse was moni-
tored and maintained at 37°C during the experiment.
Animal protocol. Animal care and experimental pro-
cedures complied with the Guide for the Care and Use of
Laboratory Animals (National Institutes of Health publica-
tion 86-23, 1985) and were approved by theMassachusetts
General Hospital Institutional Review Board. B6,
129SF2/J mice (Jackson Laboratory, Bar Harbor, Me)
were anesthetized by intraperitoneal administration of pen-
tobarbital 60 to 90 mg/kg. Thirty minutes after the induc-
tion of anesthesia, the controlled-tension tourniquet was
used to induce unilateral hind limb ischemia for 3 hours
followed by 4 or 24 hours of reperfusion. Mice remained
anesthetized throughout the period of ischemia and the
initial early reperfusion interval (4 hours). Mice in the
24-hour reperfusion group were allowed to recover from
anesthesia after the initial 4 hours of reperfusion and were
returned to their cages. After 4 or 24 hours of reperfusion,
the animals were killed (pentobarbital 200 mg/kg intra-peritoneally), and both the I/R and contralateral limbs
were harvested and the skin removed. Sham animals were
treated exactly as the experimental animals except that no
tension was applied to the tourniquet.
Tissue KC and MIP-2 levels. The entire hind limb 2
mm below the tourniquet and in the corresponding region
of the contralateral limb was removed immediately after
death in experimental and sham mice. The skin was re-
moved, and skeletal muscle samples were snap-frozen in
liquid nitrogen immediately after harvest and stored at
80°C until analysis. Muscle samples were homogenized
in a test tube containing 1 mL of RIPA buffer with 10 L
of protease inhibitor cocktail (8340; Sigma, St Louis, Mo)
and placed on ice for 30 minutes. The samples were then
sonicated for 20 seconds and incubated on ice for an
additional 30 minutes. These samples were then centri-
fuged at 10,000g for 10 minutes. The supernatants were
then decanted, aliquoted, and frozen (80°C) until anal-
ysis via enzyme-linked immunosorbent assay (ELISA).
Enzyme-linked immunosorbent assay. ELISA kits
(Quantikine mouse KC and MIP-2; R&D Systems, Min-
neapolis, Minn) using the quantitative sandwich enzyme
immunoassay technique were used to determine levels of
cytokines in the protein extracts. According to the manu-
facturer (R&D Systems), at 50 ng/mL concentration, no
significant cross-reactivity or interference from the related
mouse chemokines C10, JE/Monocyte Chemoattractant
Protein-1 (JE/MCP-1), MIP-1, MIP-1, or MIP-2 was
detected with the KC ELISA kit. Similarly, at 45 ng/mL,
no significant cross-reactivity or interference from the re-
lated chemokines C10, JE/Monocyte Chemoattractant
Protein-1 (JE/MCP-1), MIP-1, or MIP-1 was detected
with the MIP-2 ELISA kit. With the MIP-2 kit, cross-
reactivity with murine recombinant KC was detected at
0.03%. The ELISA plates were read on a Spectromax plate
reader (Molecular Devices, Sunnyvale, Calif). The protein
content values were extrapolated off the standard curve and
normalized to the total protein concentration, which was
determined with a BCA Protein Assay Reagent Kit (Pierce
Biotechnology, Rockford, Ill).
SerumKC assay. Oneminute after the administration
of a lethal dose of pentobarbital (200 mg/kg), mice were
decapitated, and their blood was harvested into an Eppen-
dorf tube. Serum was isolated after centrifugation at 2000g
for 20 minutes at 4°C. After centrifugation, serum was
frozen at 80°C until ELISA analysis. On the day of
ELISA analysis, serum samples were thawed in a 37°C
water bath and then loaded on an ELISA plate (R&D
Systems). Serum KC levels were extrapolated directly from
a standard curve.
Messenger RNA isolation and real-time polymerase
chain reaction. Total RNA was isolated from tissue after
muscle homogenization in TRIzol reagent (Invitrogen,
Carlsbad, Calif), followed by chloroform phase separation
and 2-propanol precipitation. Total RNA samples were
purified by lithium chloride precipitation. The concentra-
tion of total RNA was determined by measuring the ab-
sorption at 260 nm, and the purity of the RNAwas assessed
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nm. Equal amounts of total RNA were reverse-transcribed
by using the SuperScript First-Strand Synthesis System
(Invitrogen). Quantitative reverse transcription-polymer-
ase chain reaction was performed on 2.5-L complemen-
tary DNA aliquots by using a QuantiTect SYBR Green
PCR buffer (Qiagen, Valencia, Calif) and an iCycler iQ
system (Bio-Rad Laboratories, Hercules, Calif). Primer
pairs designed for the targeted template were used in that
reaction and had the following sequences: KC—forward,
5=-GTCAACCACTGTGCTAGTAGAAG-3=; reverse, 5=-
GTCCTTTGAACGTCTCTGTCC-3=; MIP-2—forward,
5=-CTGGGGAGAGGGTGAGTTG-3=; reverse, 5=-GCT-
GTTCTACTCTCCTCGGTG-3=. PCR fragments con-
taining the target sequence were used as external standards.
The reverse transcription-polymerase chain reaction was
performed under the following conditions: 94°C for 30
seconds, 55°C for 30 seconds, and 72°C for 30 seconds for
a total of 40 cycles. A melting curve was generated at the
end of the reaction to confirm the specificity of the poly-
merase chain reaction products. A standard curve was plot-
ted based on the threshold cycle against the log of the
standard concentration by using a dilution series of the
standards. The concentration of the polymerase chain reac-
tion target was calculated by comparing the threshold cycle
of the unknowns with the standard curve. Data are ex-
pressed as relative -fold change compared with sham
mRNA levels. Sham mRNA was harvested from the hind
limbs of mice subjected to 7 hours of anesthesia alone at
37°C in the absence of I/R.
Estimation of tissue viability. Tissue viability was
assessed by the reduction of a tetrazolium salt to water-
insoluble colored formazan crystals by electron carriers and
oxidative enzymes in the mitochondria of viable tissue.
Harvested limb tissue harvested immediately below the
tourniquet was cut into three pieces to increase surface area
and enhance tissue uptake of the tetrazolium salt. Each
piece was weighed and placed in a small tube with 3 mL of
phosphate-buffered saline (PBS; pH 7.4) supplemented
with 300 L of 1 mg/mL 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium (Sigma). The samples were incu-
bated for 3 hours at 37°C in the dark on a rotating mixer.
The samples were then removed, washed with distilled
water, and blotted dry. The water-insoluble formazan salt
was extracted in 3 mL of 2-propanol for 6 hours at 37°C in
the dark on a rotating mixer. Aliquots of 200 L were
removed, and the absorbance was determined at 570 nm by
using a microplate reader. The tissue samples were then
dried at 90°C for 24 hours. The viability index is expressed
as the optical density relative to dry tissue weight in the
experimental vs the nonischemic contralateral limb.
Determination of tissue edema. The extent of skele-
tal muscle edema was determined by measuring tissue wet
to dry weight ratio. Immediately after harvest, tissue sam-
ples were blotted, weighed, and placed in a drying oven at
55°C until a constant weight was obtained. Muscle edema
is detected by a relative increase in the wet to dry weight
ratio.Immunohistochemistry. Harvested mouse hind
limbs were fixed in 10% buffered formalin, decalcified, and
embedded in paraffin. Six-micrometer-thick transverse sec-
tions were mounted on positively charged slides and sub-
sequently deparaffinized in xylene and rehydrated in graded
alcohols. The slides were incubated for 5 minutes in 1%
hydrogen peroxide, washed in PBS, and then sequentially
blocked first with 1% serum at room temperature (1 hour)
and then with biotin reagent for 15 minutes. After block-
ing, slides were incubated with either anti-mouse MIP-2
(15g/mL) or anti-mouse KC (1g/mL) goat polyclonal
immunoglobulin G (R&D Systems) in PBS overnight at
room temperature. After incubation with the primary anti-
bodies, the slides were washed three times in PBS and then
incubated with biotin-conjugated donkey anti-goat as a
secondary antibody for 1 hour. The slides were rinsed three
times with PBS and developed with 3,3=-diaminobenzidine
Fig 1. Skeletal muscle chemokine protein levels during ischemia/
reperfusion. Keratinocyte derived cytokine (KC) levels (A) were
not increased during ischemia or reperfusion in the ischemic or
contralateral limbs. After 4 and 24 hours of reperfusion, tissue KC
levels increased when compared with ischemic, sham, and con-
tralateral limbs (*P  .001 vs sham). Macrophage inflammatory
protein (MIP) levels (B) were not increased during ischemia or
after 4 hours of reperfusion in ischemic or contralateral limbs. In
contrast, after 24 hours of reperfusion, MIP levels were markedly
increased in the reperfused (P .001 vs all), but not the contralat-
eral, limb.chromogen reagent solution (R&D Systems) according to
increased levels of chemokines in reperfused skeletal muscle.
(B) were increased only after 4 hours of reperfusion (*P  .001).
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with hematoxylin and examined by light microscopy.17
Statistical analysis. Statistical analysis was performed
with InStat (GraphPad, San Diego, Calif). Skeletal muscle
tissue edema, viability, and KC/MIP-2 mRNA/protein
levels were compared by using analysis of variance with
Tukey-Kramer post hoc tests.
RESULTS
Skeletal muscle chemokine protein levels. Three
hours of ischemia (Fig 1,A) did not increase the absolute
level of KC protein in skeletal muscle as compared with
sham (3.2  1.1 vs 2.1  1.0 pg/mg protein; P  .05).
After 4 hours of reperfusion, however, tissue KC levels
increased significantly to 18.4  3.0 pg/mg protein (P 
.001 vs ischemia and sham) only in the reperfused limb.
After 24 hours of reperfusion, tissue KC levels continued to
increase to 52  8 pg/mg protein in the reperfused, but
not the contralateral, limb (P  .001 vs sham and 3 hours
of ischemia; P  .01 vs 4 hours of reperfusion). MIP-2
protein levels were not significantly increased after 3 hours
of ischemia or 4 hours of reperfusion (Fig 1, B). By 24
hours of reperfusion, MIP-2 protein levels markedly in-
creased only in the reperfused limb (21.9  4.9 pg/mg
protein; P .001 vs all intervals). There was no increase in
MIP-2 levels in the contralateral limbs when compared
with sham animals during 3 hours of ischemia or any
interval of reperfusion. These results indicate that 3 hours
of ischemia alone is not a stimulus for KC and MIP synthe-
sis. It would seem that reperfusion is the primary variable
responsible for KC and MIP protein synthesis after 3 hours
of ischemia in skeletal muscle.
Serum KC levels. Three hours of ischemia alone did
not increase serum levels of KC when compared with sham
mice (sham, 175  40 pg/mL; ischemia alone, 188  35
pg/mL; not significant) (Fig 2). In contrast, serum KC
levels were increased after both 4 hours (600 95 pg/mL;
P  .01 vs sham) and 24 hours (816  100 pg/mL; P 
.001 vs sham) of reperfusion. These data indicate that there
is a direct relationship between the increase in KC observed
Table. Tissue viability and edema
Variable
Viability: OD570
of reperfused vs
contralateral
limb
Edema: wet to
dry ratio
4 h of reperfusion,
I/R limb
52%  4%* 7.3  0.2†
24 h of reperfusion,
I/R limb
61%  9%* 6.4  0.4†
Sham I/R, sham
limb
103%  3% 4.0  0.1
Data are mean  SE.
OD570, Optical density; I/R, ischemia/reperfusion.
*P  .01 vs sham.
†P  .001 vs sham.Fig 2. Serum levels of KC during ischemia/reperfusion. Serum
KC levels were not increased compared with sham levels during 3
hours of ischemia alone (IA). In contrast, after 3 hrs ischemia and
4 hours of reperfusion (I/4R, *P.01) and 3 hrs ischemia and 24
hours reperfusion (I/24R, **P.001), there was a substantial
progressive increase in serum KC levels that did correlate withFig 3. Steady-state levels of chemokine messenger RNA
(mRNA) in skeletal muscle ischemia/reperfusion. KC mRNA (A)
levels were increased only after 4 and 24 hours of reperfusion. In
contrast, macrophage inflammatory protein (MIP) mRNA levelsin skeletal muscle and its appearance in the serum upon
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reperfusion seems to mimic the profile of MIP-2, as previ-
ously described by Wakai et al.8
Chemokine mRNA levels. Three hours of ischemia
resulted in a modest increase in KC mRNA (1.76  0.2-
fold increase; Fig 3A). Four and 24 hours of reperfusion
resulted in significantly increased steady-state levels of KC
mRNA (4 hours, 15.6  4.3-fold increase; 24 hours, 11.2
 2.4-fold vs 1.76  0.2-fold; P  .01 vs ischemia alone).
MIP-2 mRNA levels (Fig 3B) did not increase significantly
after 3 hours of ischemia and 24 hours of reperfusion. After
4 hours of reperfusion, MIP-2 mRNA levels were signifi-
cantly increased to 41.2 14-fold. These data also confirm
that ischemia alone is not a sufficient stimulus for upregu-
lation of the steady-state level of MIP and KC mRNA and
that reperfusion is the primary stimulus for the increased
steady-state levels of chemokine mRNA in skeletal muscle.
Skeletal muscle viability. Skeletal muscle viability af-
ter 4 hours of reperfusion was not different from viability
after 24 hours of reperfusion (Table), even though tissue
KC and MIP levels remained increased over this same time
interval. On the basis of these findings, it does not seem
that the ongoing presence of these chemokines contributes
to temporal changes in tissue viability over the time period
examined in this study.
Skeletal muscle edema. Between 4 and 24 hours of
Fig 4. Immunohistochemistry for tissue chemokines (o
out the reperfused muscle fibers at 24 hours, in contr
nonspecific. Macrophage inflammatory protein 2 (MIP-2
when compared with the pattern in sham tissue.reperfusion, there was no significant change in the extent oftissue edema (Table). These findings indicate that even
though tissue levels of MIP-2 and KC remained increased
up to 24 hours, there was no evidence of an ongoing
increase in tissue edema. This result may mean that the
degree of tissue inflammation plateaus after 4 hours of
reperfusion independently of increased skeletal muscle tis-
sue chemokine levels.
Skeletal muscle immunohistochemistry. After 24
hours of reperfusion, staining for tissue KC and MIP was
clearly visible (Fig 4). These findings provide an anatomic
correlation with the protein ELISA data described previ-
ously. KC and MIP-2 protein staining could not be identi-
fied in arteries or inflammatory cells. Intense staining for
MIP and KC was detected primarily in skeletal muscle.
DISCUSSION
This study is the first to directly document increased
levels of MIP-2 and KC protein and their respective mR-
NAs in skeletal muscle after acute hind limb I/R. This
observation is important primarily because to date, the
CXC chemokines have been primarily implicated in the
development of remote tissue injury in the lung after acute
hind limb I/R. Convincing evidence from other studies
documents increased levels of circulatingMIP-2 only in the
serum8 and lungs18 of rodents subjected to hind limb I/R.
In one study, substantial levels of chemokines were even
l magnification,40). KC staining was intense through-
sham tissue, in which the staining was minimal and
ning was similarly intense in reperfused tissue, especiallyrigina
ast to
) staifound to accumulate in the lung before limb reperfusion,18
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chemokines are actually synthesized and whether their syn-
thesis occurs during ischemia or during reperfusion. Al-
though there is considerable evidence to support a role for
neutrophils in the development of limb I/R,2,19-22 there is
no convincing evidence that localizes chemokine synthesis
to the reperfused or ischemic hind limb. Because numerous
in vitro and in vivo studies have clearly documented the role
of MIP-2 and KC in mediating neutrophil chemotaxis,23
these experiments were designed to determine whether
these chemokines actually accumulate in the ischemic or
reperfused limb. In many other tissues, chemokines, rather
than primary chemoattractants, are believed to play a role in
the local expansion of the inflammatory response.18,24
The skeletal muscle levels of KC protein increased with
4 hours of reperfusion and continued to increase even after
24 hours of reperfusion (Fig 1, A). In contrast, MIP-2
protein levels did not increase significantly during the initial
4 hours of reperfusion, but it did markedly increase by 24
hours (Fig 1, B). In concert with increased KC protein in
skeletal muscle, serum levels of KC increased during reper-
fusion, but not during ischemia (Fig 2). These data are the
first to demonstrate increased plasma levels of KC immedi-
ately after limb reperfusion. The pattern of KC accumula-
tion in serum parallels the pattern observed for MIP-2 in
plasma after reperfusion.8,18 Because plasma levels of KC
are not increased in serum or skeletal muscle during isch-
emia, these data indicate that the chemokines found in lung
tissue before reperfusion18 may not originate in skeletal
muscle. Even though serum levels of chemokine KC (Fig 2)
and MIP-28 are increased during reperfusion,8 these data
show no significant increase in chemokine protein accumu-
lation in the contralateral limb. This suggests that the
reports of accumulation of chemokines in lung,18 hepatic,5
and renal tissue24 after reperfusion are specific for those
reperfused tissue beds and that this is not a nonspecific
process. Because we (Fig 2) and others (Wakai et al8) have
demonstrated an increase in chemokines in serum during
reperfusion, the accumulation of chemokines in remote
tissue during reperfusion must be a tissue-specific occur-
rence. If chemokine accumulation were a nonspecific pro-
cess, then we would expect to detect chemokines in the
nonischemic and nonreperfused tissues. It is important to
determine where chemokines are synthesized because these
proinflammatory proteins are commonly believed to have
autocrine and paracrine effects in the locale where they are
synthesized, rather than to have a hormonal effect in re-
mote areas.25 The specific localization of MIP and KC
protein to the reperfused limb establishes this postischemic
tissue as a major site of chemokine synthesis. Furthermore,
by localizing the synthesis of these chemokines to the
reperfused limb, it may be possible to direct antichemokine
therapeutic interventions toward the ischemic limb before
reperfusion. Chemokine antagonists administered before
reperfusion might have local and systemic benefits
throughout the reperfusion period.
To understand whether the levels of these cytokines in
the tissue were related to active cytokine synthesis as op-posed to local deposition, we sought to quantify the steady-
state levels of KC and MIP-2 mRNA in the ischemic and
reperfused tissue (Fig 3). This analysis revealed a sustained
12- to 15-fold increase in KC mRNA during 4 and 24
hours of reperfusion. These increases did directly correlate
with the increase in KC levels in the skeletal muscle, thus
fortifying our hypothesis that KC is synthesized locally in
the postischemic skeletal muscle. Analysis of the steady-
state levels of MIP-2 mRNA in these tissues revealed no
direct correlation between tissue mRNA levels and tissue
protein levels; ie, there was a marked increase in MIP-2
mRNA during the initial 4 hours of reperfusion that was
not associated with a significant increase in measurable
MIP-2 protein. Measurable chemokine protein levels in
tissue become apparent when local synthesis results in
saturation of chemokine receptors. In contrast, by 24
hours, the MIP protein levels markedly increased but were
not associated with an increase in MIP mRNA. These
findings suggest that MIP protein synthesis may be delayed
during early reperfusion. It is also likely that the levels of
chemokine measured in the tissue are related to saturation
of receptors, thus suggesting that excess (ie, unbound)
MIP-2 chemokine levels cannot be measured until 24
hours of reperfusion. The relative downregulation of
MIP-2 mRNA during reperfusion may be due to the satu-
ration of the CXC receptor by 24 hours when MIP-2
protein levels are significantly increased (Fig 1, B).
Reperfusion injury is often associated with increased
levels of tissue edema, thought to be related primarily to
inflammation and changes in vascular permeability.26-28 It
is interesting to note that after 4 and 24 hours of reperfu-
sion, there was no progressive increase in edema or tissue
injury up to 24 hours (Table), despite the ongoing accu-
mulation of MIP and KC protein in the muscle (Fig 1A,
1B). This finding suggests that the delayed appearance of
MIP-2 protein during reperfusion does not exacerbate the
inflammatory response or decrease skeletal muscle viability.
Longer-term studies of at least 7 to 10 days will be neces-
sary to determine whether these proteins may play a role in
the angiogenic/healing process after reperfusion29 (Fig 4).
Further clues into the specific roles for CXC chemo-
kines in postischemic skeletal muscle will likely come from
studies of CXC receptor antagonists. Recent studies with
truncated CXC analogues indicate that these receptors
modulate acute inflammation in vivo.23 Interest in the
CXC receptors has increased substantially because of data
that indicate that the human immunodeficiency virus 1
enters cells through the CXC receptors.30 Oral CXC che-
mokine receptor 4 antagonists have been used to decrease
human immunodeficiency virus 1 activity in mice.31 Be-
cause mRNA and protein for these important chemokines
tend to increase in skeletal muscle primarily during reper-
fusion, it may be possible to preload ischemic limbs with
receptor antagonists before and throughout reperfusion.
In summary, these studies indicate that skeletal muscle
is a major source of CXC chemokine synthesis during
reperfusion. These results indicate that MIP-2 and KC are
synthesized locally in the skeletal muscle and are not non-
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muscle tissue. It is not clear from this report whether these
chemokines have either inflammatory or angiogenic prop-
erties. On the basis of the biochemical profile described in
this article and our emerging knowledge regarding their
biologic activity in vivo, the exclusive synthesis of chemo-
kines during reperfusion suggests that strategies directed
toward modulating chemokine transcription, translation,
or receptor blockade during early reperfusion may be di-
rected locally into skeletal muscle during reperfusion.
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